Add to watchlist:

Only registered members can add into watchlist !

Register here !
ImmuPharma PLC
Deal ImmuPharma PLC Tax Free* Losses can exceed
your initial deposit
*subject to change and depends on individual circumstances.

ImmuPharma PLC is a pharmaceutical company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents. The...

Read more

Immupharma gets Lupus treatment boost as US allows smaller final trials

The number of patients for the phase III programme has been reduced to two studies with 200 patients each.

Immupharma’s (LON:IMM) potential blockbuster treatment for Lupus, Lupuzor, has received a major boost after the US authorities reduced the number of phase III trials required for the new drug.

Lupuzor’s special protocol assessment (SPA) status has been amended by the US Food and Drug Administration (FDA) so that the number of patients for the phase III programme has been reduced to two studies with 200 patients each.

Phase III trials are normally carried out on much larger groups to assess efficacy, monitor side effects and compare with rival treatments.

Immupharma said the number of people in its trials is lower than other drugs in clinical trials for lupus and underpins the efficacy shown by Lupuzor. The design of the phase III study is also similar to that of the Immupharma phase IIb study, it said, adding it is now completing the manufacture of the drugs for the phase III trials.

Dr Robert Zimmer, Immupharma’s president and chief scientific officer, was delighted with the amended staus of Lupuzor.

“The amended SPA is a tremendous success and validation of our development efforts and the reduced number of patients, due to the unrivalled efficacy that Lupuzor has shown in phase IIb means that the cost of the phase III trial will also be substantially lower.

“The phase III programme has a similar design to our phase IIb study which demonstrated substantial efficacy compared to other drugs in Lupus clinical trials."

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.